周一，H.C. Wainwright对Alkermes（NASDAQ: ALKS）股票维持中性评级，目标价保持在37.00美元不变。在Alkermes介绍其orexin产品组合策略的分析师会议后，该公司对Alkermes的前景越发乐观。这种兴趣的提升是在公司公布了令人鼓舞的早期1b期数据并将ALKS-2680推进到2期研究之后。 ALKS-2680目前正在研究其治疗1型嗜睡症、2型嗜睡症和特发性嗜 ...

Seltorexant is one of J&J’s most promising neuroscience candidates. The human orexin-2 receptor selective agonist produced ...

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ALKS stock, giving a Buy rating on September 26. Uy Ear has given his ...

Centessa Pharmaceuticals plc recently detailed the discovery and preclinical characterization of a novel potent and selective orexin OX2 receptor agonist, ORX-142.

周四，Baird重申了对Alkermes (NASDAQ:ALKS)的"跑赢大市"评级和38.00美元的目标价。这一背书是在Alkermes最近举行的投资者活动之后做出的，该活动回顾了公司的Orexin产品组合战略，强调了orexin类药物在嗜睡症之外多种适应症中的潜力，而嗜睡症目前是其主要研究领域。 该活动展示了orexin类药物的多功能性，表明它可能在多个医疗适应症中显著有效。这一进展凸显了公 ...

Indeed, the Patient Odyssey Survey II conducted by the Restless Legs Syndrome Foundation in 2022 found RLS significantly ...

Johnson & Johnson is jettisoning several programs, with three of the culls taking place in the neuroscience field. | Johnson ...

Johnson & Johnson is cutting several programs—most of which are in neurology and psychiatry—as the company also pulls back from the infectious diseases market.

Alkermes plc (Nasdaq: ALKS) announced today that it will host an investor event for financial analysts and institutional investors on Wednesday, Oct. 9, 2024 starting at 10:00 a.m. EDT in Waltham, ...

Want to get free Modafinil samples without a prescription? In this guide, you will discover the best places to order a free ...